A novel model-based approach for dose determination of glycopyrronium bromide in COPD

BMC Pulmonary Medicine

Donald Banerji¹  Michael Looby³  Vijay Alagappan²  Michael Gibbs²  Didier Renard³  Tim Overend²  Helen Arievich⁴ 

[1] Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, UK;Novartis Pharma AG, Basel, Switzerland;Medars GmbH, Berlin, Germany

关键词: Adherence;    LAMA;    Dose–response;    COPD;    Twice-daily;    Once-daily;    Glycopyrronium bromide (NVA237);   

Others  :  1136301
DOI  :  10.1186/1471-2466-12-74

 received in 2012-07-23, accepted in 2012-11-28,  发布年份 2012

【 摘 要 】

Background

Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic antagonist in development for treatment of COPD. This study compared the efficacy and safety of once-daily (OD) and twice-daily (BID) glycopyrronium bromide regimens, using a novel model-based approach, in patients with moderate-to-severe COPD.

Methods

Double-blind, randomized, dose-finding trial with an eight-treatment, two-period, balanced incomplete block design. Patients (smoking history ≥10 pack-years, post-bronchodilator FEV₁ ≥30% and <80% predicted, FEV₁/FVC <0.7) were randomized to one of 16 independent sequences for 28 days. Primary endpoint: mean trough FEV₁ at Day 28.

Results

385 patients (mean age 61.2 years; mean post-bronchodilator FEV₁ 53% predicted) were randomized; 88.6% completed. All OD and BID dosing regimens produced dose-dependent bronchodilation; at Day 28, increases in mean trough FEV₁ versus placebo were statistically significant for all regimens, ranging from 51 mL (glycopyrronium bromide 12.5 μg OD) to 160 mL (glycopyrronium bromide 50 μg BID). Pharmacodynamic steady-state was reached by Day 7. There was a small separation (≤37 mL) between BID and OD dose–response curves for mean trough FEV₁ at steady-state in favour of BID dosing. Over 24 hours, separation between OD and BID regimens was even smaller (FEV₁ AUC_0-24h maximum difference for equivalent daily dose regimens: 8 mL). Dose–response results for FEV₁ at 12 hours, FEV₁ AUC_0-12h and FEV₁ AUC_0-4h at steady-state showed OD regimens provided greater improvement over placebo than BID regimens for total daily doses of 25 μg, 50 μg and 100 μg, while the reverse was true for OD versus BID regimens from 12–24 hours. The 12.5 μg BID dose produced a marginally higher improvement in trough FEV₁ versus placebo than 50 μg OD, however, the response at 12 hours over placebo was suboptimal (74 mL). Glycopyrronium bromide was safe and well tolerated at all doses.

Conclusions

Glycopyrronium bromide 50 μg OD provides significant bronchodilation over a 24 hour period, and in terms of FEV₁ AUC_0-24h is not significantly different than the same total daily dose administered BID. Importantly, OD dosing may confer better patient adherence. The results are consistent with previous glycopyrronium bromide studies and support once-daily dosing of glycopyrronium bromide 50 μg in patients with moderate-to-severe COPD.

Trial registration

ClinicalTrials.gov: NCT01119950

【 授权许可】

   
2012 Arievich et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Global initiative for chronic obstructive lung diseases (GOLD): Executive Summary: Global Strategy for the Diagnosis, Management, and Prevention of COPD. (http://www.goldcopd.com webcite) 2010
• [2]World Health Organization (WHO): The global burden of disease 2004 update. Geneva, Switzerland: World Health Organization; 2008.
• [3]Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M, UPLIFT Study Investigators: Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010, 36:65-73.
• [4]Vogelmeier C, Banerji D: NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Ther Adv Respir Dis 2011, 5:163-173.
• [5]Verkindre C, Fukuchi Y, Flémale A, Takeda A, Overend T, Prasad N, Dolker M: Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010, 104:1482-1489.
• [6]Kerwin E, Hébert J, Gallagher N, Martin C, Overend T, Alagappan VKT, Lu Y, Banerji D: Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study. Eur Respir J 2012, 40:1106-14.
• [7]Overend T, Lu Y, Dolker M, Banerji D: Dose response of NVA237, a long-acting muscarinic antagonist for the treatment of COPD. Am J Respir Crit Care Med 2010, 181:A4422.
• [8]Fogarty C, Hattersley H, Di Scala L, Drollmann A: Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010, 105:334-342.
• [9]Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Güçlü SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK: Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 2010, 23:438-444.
• [10]Renard D, Looby M, Kramer B, Lawrence D, Morris D, Stanski DR: Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res 2011, 12:54. BioMed Central Full Text
• [11]Renard D, Stanski DR, Morris D, Looby M: Improving dose–response assessments of bronchodilators, using indacaterol as an example. RDD Europe 2011, 1:167-176.
• [12]Global initiative for chronic obstructive lung diseases (GOLD): Executive Summary: Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2008. http://www.goldcopd.com webcite
• [13]Donohue JF: Minimal clinically important differences in COPD lung function. COPD 2005, 2:111-124.
• [14]Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten A-M, Falques M, Caracta CF, Gil EG: Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012, 141:745-752.
• [15]Agusti A, Vestbo J: Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 184:507-513.
• [16]Bourbeau J, Bartlett SJ: Patient adherence in COPD. Thorax 2008, 63:831-838.
• [17]Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
• [18]Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM: Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med 2007, 101:1398-1405.
• [19]Tashkin DP, Fabbri LM: Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010, 11:149. BioMed Central Full Text
• [20]Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS: Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011, 105:435-441.
• [21]Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Yates BS, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
• [22]Beeh KM, Beier J: The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010, 27:150-159.
• [23]Vestbo J, Anderson JA, Calverley PMA, Celli B, Ferguson GT, Jenkins C, Knobil K, Willits LR, Yates JC, Jones PW: Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009, 64:939-943.
• [24]Rand CS, Nides M, Cowles MK, Wise RA, Connett J: Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am J Respir Crit Care Med 1995, 152:580-588.
• [25]van Grunsven PM, van Schayck CP, van Deuveren M, van Herwaarden CL, Akkermans RP, van Weel C: Compliance during long term treatment with fluticasone propionate in subjects with early signs of asthma or chronic obstructive pulmonary disease (COPD): results of the Detection, Intervention, and Monitoring Program of COPD and Asthma (DIMCA) Study. J Asthma 2000, 37:225-234.
• [26]Haupt D, Krigsman K, Nilsson JL: Medication persistence among patients with asthma/COPD drugs. Pharm World Sci 2008, 30:509-514.
• [27]Krigsman K, Nilsson JL, Ring L: Refill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected repeat prescriptions. Pharmacoepidemiol Drug Saf 2007, 16:441-448.
• [28]Krigsman K, Moen J, Nilsson JL, Ring L: Refill adherence by the elderly for asthma/chronic obstructive pulmonary disease drugs dispensed over a 10-year period. J Clin Pharm Ther 2007, 32:603-611.
• [29]D'Urzo A, Ferguson G, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011, 12:156. BioMed Central Full Text
• [30]Beeh KM, Singh D, Di Scala L, Drollmann A: Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J COPD 2012, 7:503-513.
• [31]Korenblat PE, Hebert J, Gallagher N, Martin C, Banerji D, Lu Y: NVA237 once daily improves dyspnea and health-related quality of life in patients with COPD: the GLOW2 trial. Am J Respir Crit Care Med 2012, 185:A2254.
• [32]Sechaud R, Renard D, Zhang-Auberson L, de la Motte S, Drollmann A, Kaiser G: The pharmacokinetics of multiple inhaled NVA237 doses at four dose levels in COPD patients. Int J Clin Pharmacol Ther 2012, 50:118-128.
• [33]Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G: Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res 2011, 12:40. BioMed Central Full Text